What does Aditum Bio do?

Aditum Bio is a biotech venture capital firm based in Oakland, California, focused on translating scientific discoveries into new medicines. Co-founded in 2019 by Joe Jimenez and Dr. Mark Fishman, the firm operates a unique model that emphasizes advancing drug candidates through the translational phase of development. The company specializes in in-licensing promising drug candidates and forming dedicated clinical-stage companies to develop these therapies. Aditum Bio has launched thirteen companies across three funds, with notable successes including Versanis, which was sold to Eli Lilly for $1.9 billion. The firm targets various therapeutic areas, including autoimmune and inflammatory diseases, substance use disorders, and cardiovascular disease. Aditum Bio collaborates with external organizations, such as TrialSpark, to enhance clinical trial execution and reduce costs.